Table 1.
Participant characteristics
| Characteristic | Data |
|---|---|
| Total patients, N | 18 |
| Men, n (%) | 8 (44) |
| Age, years | 48 [39, 55] |
| Onset age, years | 20 [15, 27] |
| Diabetes duration, years | 26 [20, 30] |
| Body weight, kg | 77 (12) |
| BMI, kg/m2 | 24.8 (2.8) |
| eGFR, mL/min/1.73 m2 | 110 [95, 116] |
| HbA1c, % | 7.5 [7.0, 8.4] |
| HbA1c, mmol/mol | 58 [53, 68] |
| Total cholesterol, mmol/L | 4.4 [4.0, 5.3] |
| LDL cholesterol, mmol/L | 2.4 [2.1, 3.0] |
| HDL cholesterol, mmol/L | 1.4 [1.3, 1.7] |
| Urine albumin-to-creatinine ratio, mg/g | 5 [3, 8] |
| Fasting venous plasma glucose, mmol/L | 8.8 [7.9, 10.9] |
| Fasting C-peptide, pmol/L | 479 [314, 711] |
| Fasting insulin, pmol/L | 38 [21, 53] |
| HOMA2 insulin resistance | 1.28 [1.03, 1.92], n = 15 |
| HOMA2 β-cell function, % | 37 [24, 48], n = 15 |
| Complications, n (%) | |
| Retinopathy | 7 (39) |
| Nephropathy | 2 (11) |
| Neuropathy | 2 (11) |
| Cerebrovascular disease | 0 (0) |
| Coronary heart disease | 1 (6) |
| Peripheral arterial disease | 1 (6) |
| Glucose-lowering drugs, n (%) | |
| SU | 16 (89) |
| GLP-1RA | 3 (17) |
| Metformin | 3 (17) |
| Repaglinide | 1 (6) |
| DPP-4 inhibitor | 6 (33) |
| Insulin, bolus | 2 (11) |
| Insulin, basal | 3 (17) |
Data are reported as mean (SD) or median [quartile 1, quartile 3]. HOMA2 measures are only reported for participants not treated with insulin (n = 15). DPP-4, dipeptidyl peptidase-4; GLP-1RA, glucagon-like peptide-1 receptor agonist.